公开(公告)号：US20040146926A1

公开(公告)日：2004-07-29

申请号：US10787018

申请日：2004-02-24

Applicant: ChemoCentryx, Inc.

Inventor： Jennifa Gosling ,  Daniel J. Dairaghi ,  Michael Hanley ,  Zhenhua Miao ,  Dale Talbot ,  Thomas J. Schall

IPC: C12Q001/68 ,  C07K014/74

CPC classification number: C07K14/521 ,  C07K14/7158 ,  C07K2319/00 ,  G01N33/5088 ,  G01N33/531 ,  G01N33/6863 ,  G01N2500/00

Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.

Abstract translation: 本发明提供编码新趋化因子受体CCX CKR的多肽和多核苷酸。 本发明还提供了用于鉴定调节受体的活性或表达的试剂以及用于检测受体表达的方法的试剂和方法。

公开(公告)号：US20040039035A1

公开(公告)日：2004-02-26

申请号：US10654112

申请日：2003-09-02

Applicant: Tularik Inc. ,  ChemoCentryx, Inc.

Inventor： Tassie Collins ,  Daniel J. Dairaghi ,  Hossen Mahmud ,  Brian E. McMaster ,  Julio C. Medina ,  Thomas J. Schall ,  Feng Xu ,  Xuemei Wang

IPC: A61K031/426 ,  A61K031/4245 ,  A61K031/381 ,  A61K031/18 ,  A61K031/34

CPC classification number: C07D417/12 ,  A61K31/00 ,  A61K31/265 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/36 ,  A61K31/381 ,  A61K31/4245 ,  A61K31/426 ,  C07D277/42 ,  C07D277/82 ,  C07D513/04

Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

Abstract translation: 提供了结合CCR4趋化因子受体的化合物和组合物，其可用于治疗与CCR4活性相关的疾病，例如接触性超敏反应。

公开(公告)号：US20030119854A1

公开(公告)日：2003-06-26

申请号：US10279353

申请日：2002-10-23

Applicant: ChemoCentryx, Inc.

Inventor： Thomas J. Schall ,  Daniel J. Dairaghi ,  Brian E. McMaster

IPC: A61K031/517 ,  A61K031/4709 ,  A61K031/47 ,  C07D239/72 ,  C07D43/02 ,  C07D217/22 ,  C07D41/02

CPC classification number: C07D239/91

Abstract: Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.

Abstract translation: 提供了与CXCR3趋化因子受体结合的化合物和组合物，其可用于治疗与CXCR3活性相关的疾病，如多发性硬化症。

公开(公告)号：US20030114423A1

公开(公告)日：2003-06-19

申请号：US10233336

申请日：2002-08-29

Applicant: ChemoCentryx, Inc.

Inventor： Brian E. McMaster ,  Thomas J. Schall ,  Mark Penfold ,  J.J. Wright ,  Daniel J. Dairaghi

IPC: A61K031/675 ,  A61K031/5377 ,  A61K031/496 ,  A61K031/4709 ,  A61K031/4178 ,  A61K031/454

CPC classification number: C07D207/08 ,  A61K31/075 ,  A61K31/135 ,  A61K31/4709 ,  C07D207/27 ,  C07D211/14 ,  C07D211/26 ,  C07D231/12 ,  C07D241/04 ,  C07D295/088 ,  C07D295/096 ,  C07D295/135 ,  C07D295/155 ,  C07D453/04

Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: 1 wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.

Abstract translation: 提供了使用具有下式的化合物治疗CMV和CMV相关疾病的方法：其中下标m和n各自独立地为1至2的整数; 并且R基团如说明书中所定义。

公开(公告)号：US20020132836A1

公开(公告)日：2002-09-19

申请号：US09975567

申请日：2001-10-11

Applicant: ChemoCentryx Inc.

Inventor： Daniel J. Dairaghi ,  Brian E. McMaster ,  Thomas J. Schall

IPC: A61K031/426 ,  A61K031/4245 ,  A61K031/381 ,  A61K031/357 ,  A61K031/341 ,  A61K031/18

CPC classification number: C07D417/12 ,  A61K31/00 ,  A61K31/18 ,  A61K31/265 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/36 ,  A61K31/381 ,  A61K31/4245 ,  A61K31/426 ,  C07D277/42 ,  C07D277/82 ,  C07D513/04

Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

Abstract translation: 提供了结合CCR4趋化因子受体的化合物和组合物，其可用于治疗与CCR4活性相关的疾病，例如接触性超敏反应。

公开(公告)号：US12011439B2

公开(公告)日：2024-06-18

申请号：US17820179

申请日：2022-08-16

Applicant: CHEMOCENTRYX, INC.

Inventor： Shijie Li ,  Venkat Reddy Mali ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/4545 ,  A61K31/165 ,  A61K31/357 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61K31/165 ,  A61K31/357 ,  A61K39/39541 ,  A61P35/00

Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

公开(公告)号：US11986466B2

公开(公告)日：2024-05-21

申请号：US17128500

申请日：2020-12-21

Applicant: CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： James J. Campbell ,  Rajinder Singh ,  Samuel Hwang ,  Xuesong Wu

IPC: A61K31/4433 ,  A61K31/496 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/4433 ,  A61K31/496 ,  A61K39/39533 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/39533 ,  A61K2300/00

Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:

公开(公告)号：US11951214B2

公开(公告)日：2024-04-09

申请号：US17545878

申请日：2021-12-08

Applicant: CHEMOCENTRYX, INC.

Inventor： Manmohan Reddy Leleti ,  Jay P. Powers

IPC: A61K9/48 ,  A61K31/4412

CPC classification number: A61K9/4858 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/4833 ,  A61K31/4412

Abstract: The present disclosure provides solid solution capsule formulations of Compound 1




and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

公开(公告)号：US11890276B2

公开(公告)日：2024-02-06

申请号：US17445640

申请日：2021-08-23

Applicant: ChemoCentryx, Inc.

Inventor： Petrus Bekker ,  Shichang Miao ,  Israel Charo ,  Tom Schall

IPC: A61K31/444 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4745 ,  A61K31/282 ,  A61K31/7068 ,  A61K31/337 ,  A61K31/506 ,  A61K45/06 ,  A61K31/555 ,  A61K31/53 ,  A61K38/19 ,  A61K39/395

CPC classification number: A61K31/444 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/53 ,  A61K31/555 ,  A61K31/7068 ,  A61K38/19 ,  A61K39/395 ,  A61K45/06 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/555 ,  A61K2300/00 ,  A61K31/282 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00 ,  A61K31/337 ,  A61K2300/00

Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

公开(公告)号：US11845729B2

公开(公告)日：2023-12-19

申请号：US17667289

申请日：2022-02-08

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Jaroslaw Kalisiak ,  Antoni Krasinski ,  Rebecca M. Lui ,  Jay Powers ,  Sreenivas Punna ,  Hiroko Tanaka ,  Penglie Zhang

IPC: C07D211/60

CPC classification number: C07D211/60

Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.